St. Louis (April 18, 2012) – Amerinet Choice®, the preferred portfolio subsidiary of Amerinet Inc., announces a new agreement with Amphastar Pharmaceuticals Inc. for generic injectables from International Medication Systems Ltd. (IMS).
Enoxaparin Sodium Injection, the generic equivalent to name-brand drugs for prophylaxis of deep vein thrombosis, is available in seven dosage forms. Syringe delivery is simplified with one-handed activation, and safety is enhanced via a unique passive needle guard that complies with the Needlestick Safety and Prevention Act.
This contract is currently effective through February 28, 2015.
About Amphastar Pharmaceuticals
Established in 1996, Amphastar Pharmaceuticals is a specialty and generic pharmaceutical company focusing on injectable and inhalation products. In conjunction with IMS, a registered manufacturer of sterile injectables, Amphastar currently manufactures 20 products using state-of-the-art aseptic cGMP compliant facilities staffed by highly dedicated and experienced professionals. Based in Rancho Cucamonga, Calif., the company continues to develop a portfolio targeting markets with high technical barriers. To learn more about Amphastar Pharmaceuticals or IMS, visit www.ims-limited.com.
About Amerinet, Inc.
As a leading national healthcare solutions organization, Amerinet collaborates with acute and non-acute care providers to create and deliver unique solutions through performance improvement resources, guidance and ongoing support. With better product standardization and utilization, new financial tools beyond contracting and alliances that help lower costs, raise revenue and champion quality, Amerinet enriches healthcare delivery for its members and the communities they serve. To learn more about how Amerinet can help you successfully navigate the future of healthcare reform, visit www.amerinet-gpo.com.